A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing treatments for Ewing Sarcoma, with multiple promising candidates in various clinical stages.
MD Anderson Cancer Center's Phase 1/2 trial of seclidemstat combination therapy shows promising 43% response rate in advanced MDS and CMML patients who failed prior treatments.
The FDA approved FoundationOne Liquid CDx as a companion diagnostic for niraparib and abiraterone in BRCA-mutated metastatic castration-resistant prostate cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.